The firm anticipates deploying funds to complete the integration of Biosensia, a developer of multi-analyte assays on a CLIA-waived testing platform.
Kypha develops tests for monitoring immune status and inflammation, while Biosensia's RapiPlex system can run simultaneous multiplex testing up to 24 analytes.
Dendritics develops antibodies against immune system and other cells for the discovery of targets with high diagnostic, prognostic, and therapeutic potential.
The three firms each had 510(k) clearances for multiple products from the FDA last month for marketing.
The firm's CEO said that its assay is applicable in other indications where immunosuppressive therapies are used, such as rheumatoid arthritis.
NanoString Technologies this week provided investors with a mixed bag of news as it released its second quarter earnings and financial outlook for the rest of the year.
The company's new FACSLyric flow cytometer system is for use with BD Multitest assays for assessing suspected immunological deficiencies in patients.
The deal is anticipated to increase diagnostics' share of PerkinElmer's business to about 38 percent of total revenues from the current 30 percent.